APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biologics for Severe Asthma

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Biologics for Severe Asthma Industry Growth and Trends Forecast to 2032

Report ID 173970750128 December 202594 pages

Choose your research edition.

Industry ResearchBiologics for Severe Asthma Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics for Severe Asthma Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Biologics for Severe Asthma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics for Severe Asthma Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics for Severe Asthma Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Biologics for Severe Asthma market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Biologics for Severe Asthma is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Biologics for Severe Asthma is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologics for Severe Asthma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Biologics for Severe Asthma include Teva Pharmaceuticals, Sanofi, Novartis, Roche, Regeneron Pharmaceuticals, GSK, AstraZeneca and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Biologics for Severe Asthma market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Biologics for Severe Asthma market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Biologics for Severe Asthma market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Biologics for Severe Asthma.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Biologics for Severe Asthma market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Biologics for Severe Asthma Market by Company

Teva Pharmaceuticals

Sanofi

Novartis

Roche

Regeneron Pharmaceuticals

GSK

AstraZeneca

Amgen

Biologics for Severe Asthma Segment by Type

Omalizumab

Benralizumab

Dupirumab

Mepolizumab

Reslizumab

Tezepelumab-ekko

Biologics for Severe Asthma Segment by Application

Clinic

Hospital

Other

Biologics for Severe Asthma Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics for Severe Asthma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics for Severe Asthma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics for Severe Asthma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biologics for Severe Asthma manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Biologics for Severe Asthma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Omalizumab Table 2. Major Company of Benralizumab Table 3. Major Company of Dupirumab Table 4. Major Company of Mepolizumab Table 5. Major Company of Reslizumab Table 6. Major Company of Tezepelumab-ekko Table 7. Global Biologics for Severe Asthma Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units) Table 9. Global Biologics for Severe Asthma Sales Market Share in Volume by Type (2021-2026) Table 10. Global Biologics for Severe Asthma Sales by Type (2021-2026) & (US$ Million) Table 11. Global Biologics for Severe Asthma Sales Market Share in Value by Type (2021-2026) Table 12. Global Biologics for Severe Asthma Price by Type (2021-2026) & (US$/Unit) Table 13. Global Biologics for Severe Asthma Sales by Type (2027-2032) & (K Units) Table 14. Global Biologics for Severe Asthma Sales Market Share in Volume by Type (2027-2032) Table 15. Global Biologics for Severe Asthma Sales by Type (2027-2032) & (US$ Million) Table 16. Global Biologics for Severe Asthma Sales Market Share in Value by Type (2027-2032) Table 17. Global Biologics for Severe Asthma Price by Type (2027-2032) & (US$/Unit) Table 18. North America Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units) Table 19. North America Biologics for Severe Asthma Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units) Table 21. Europe Biologics for Severe Asthma Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units) Table 23. Asia-Pacific Biologics for Severe Asthma Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units) Table 25. Latin America Biologics for Severe Asthma Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units) Table 27. Middle East and Africa Biologics for Severe Asthma Sales by Type (2021-2026) & (US$ Million) Table 28. Biologics for Severe Asthma Industry Trends Table 29. Biologics for Severe Asthma Industry Drivers Table 30. Biologics for Severe Asthma Industry Opportunities and Challenges Table 31. Biologics for Severe Asthma Industry Restraints Table 32. Global Biologics for Severe Asthma Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Biologics for Severe Asthma Revenue Market Share by Company (2021-2026) Table 34. Global Biologics for Severe Asthma Sales by Company (2021-2026) & (K Units) Table 35. Global Biologics for Severe Asthma Sales Share by Company (2021-2026) Table 36. Global Biologics for Severe Asthma Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Biologics for Severe Asthma Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Biologics for Severe Asthma Major Company Production Sites and Headquarters Table 39. Global Biologics for Severe Asthma Company, Product Type & Application Table 40. Global Biologics for Severe Asthma Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Biologics for Severe Asthma by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Biologics for Severe Asthma Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Biologics for Severe Asthma Sales by Region (2021-2026) & (K Units) Table 45. Global Biologics for Severe Asthma Sales Market Share in Volume by Region (2021-2026) Table 46. Global Biologics for Severe Asthma Sales by Region (2021-2026) & (US$ Million) Table 47. Global Biologics for Severe Asthma Sales Market Share in Value by Region (2021-2026) Table 48. Global Biologics for Severe Asthma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Biologics for Severe Asthma Sales by Region (2027-2032) & (K Units) Table 50. Global Biologics for Severe Asthma Sales Market Share in Volume by Region (2027-2032) Table 51. Global Biologics for Severe Asthma Sales by Region (2027-2032) & (US$ Million) Table 52. Global Biologics for Severe Asthma Sales Market Share in Value by Region (2027-2032) Table 53. Global Biologics for Severe Asthma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Biologics for Severe Asthma Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units) Table 56. Global Biologics for Severe Asthma Sales Market Share in Volume by Application (2021-2026) Table 57. Global Biologics for Severe Asthma Sales by Application (2021-2026) & (US$ Million) Table 58. Global Biologics for Severe Asthma Sales Market Share in Value by Application (2021-2026) Table 59. Global Biologics for Severe Asthma Price by Application (2021-2026) & (US$/Unit) Table 60. Global Biologics for Severe Asthma Sales by Application (2027-2032) & (K Units) Table 61. Global Biologics for Severe Asthma Sales Market Share in Volume by Application (2027-2032) Table 62. Global Biologics for Severe Asthma Sales by Application (2027-2032) & (US$ Million) Table 63. Global Biologics for Severe Asthma Sales Market Share in Value by Application (2027-2032) Table 64. Global Biologics for Severe Asthma Price by Application (2027-2032) & (US$/Unit) Table 65. North America Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units) Table 66. North America Biologics for Severe Asthma Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units) Table 68. Europe Biologics for Severe Asthma Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units) Table 70. Asia-Pacific Biologics for Severe Asthma Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units) Table 72. Latin America Biologics for Severe Asthma Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units) Table 74. Middle East and Africa Biologics for Severe Asthma Sales by Application (2021-2026) & (US$ Million) Table 75. Teva Pharmaceuticals Company Information Table 76. Teva Pharmaceuticals Business Overview Table 77. Teva Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolio Table 79. Teva Pharmaceuticals Recent Development Table 80. Sanofi Company Information Table 81. Sanofi Business Overview Table 82. Sanofi Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Sanofi Biologics for Severe Asthma Product Portfolio Table 84. Sanofi Recent Development Table 85. Novartis Company Information Table 86. Novartis Business Overview Table 87. Novartis Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Novartis Biologics for Severe Asthma Product Portfolio Table 89. Novartis Recent Development Table 90. Roche Company Information Table 91. Roche Business Overview Table 92. Roche Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Roche Biologics for Severe Asthma Product Portfolio Table 94. Roche Recent Development Table 95. Regeneron Pharmaceuticals Company Information Table 96. Regeneron Pharmaceuticals Business Overview Table 97. Regeneron Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolio Table 99. Regeneron Pharmaceuticals Recent Development Table 100. GSK Company Information Table 101. GSK Business Overview Table 102. GSK Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. GSK Biologics for Severe Asthma Product Portfolio Table 104. GSK Recent Development Table 105. AstraZeneca Company Information Table 106. AstraZeneca Business Overview Table 107. AstraZeneca Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. AstraZeneca Biologics for Severe Asthma Product Portfolio Table 109. AstraZeneca Recent Development Table 110. Amgen Company Information Table 111. Amgen Business Overview Table 112. Amgen Biologics for Severe Asthma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Amgen Biologics for Severe Asthma Product Portfolio Table 114. Amgen Recent Development Table 115. North America Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 116. North America Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 117. North America Biologics for Severe Asthma Sales Market Share by Country (2021-2026) Table 118. North America Biologics for Severe Asthma Sales Forecast by Country (2027-2032) & (K Units) Table 119. North America Biologics for Severe Asthma Sales Market Share Forecast by Country (2027-2032) Table 120. North America Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 121. North America Biologics for Severe Asthma Market Size by Country (2021-2026) & (US$ Million) Table 122. North America Biologics for Severe Asthma Market Share by Country (2021-2026) Table 123. North America Biologics for Severe Asthma Market Size Forecast by Country (2027-2032) & (US$ Million) Table 124. North America Biologics for Severe Asthma Market Share Forecast by Country (2027-2032) Table 125. Europe Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 126. Europe Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 127. Europe Biologics for Severe Asthma Sales Market Share by Country (2021-2026) Table 128. Europe Biologics for Severe Asthma Sales Forecast by Country (2027-2032) & (K Units) Table 129. Europe Biologics for Severe Asthma Sales Market Share Forecast by Country (2027-2032) Table 130. Europe Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 131. Europe Biologics for Severe Asthma Market Size by Country (2021-2026) & (US$ Million) Table 132. Europe Biologics for Severe Asthma Market Share by Country (2021-2026) Table 133. Europe Biologics for Severe Asthma Market Size Forecast by Country (2027-2032) & (US$ Million) Table 134. Europe Biologics for Severe Asthma Market Share Forecast by Country (2027-2032) Table 135. Asia-Pacific Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 136. Asia-Pacific Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 137. Asia-Pacific Biologics for Severe Asthma Sales Market Share by Country (2021-2026) Table 138. Asia-Pacific Biologics for Severe Asthma Sales Forecast by Country (2027-2032) & (K Units) Table 139. Asia-Pacific Biologics for Severe Asthma Sales Market Share Forecast by Country (2027-2032) Table 140. Asia-Pacific Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 141. Asia-Pacific Biologics for Severe Asthma Market Size by Country (2021-2026) & (US$ Million) Table 142. Asia-Pacific Biologics for Severe Asthma Market Share by Country (2021-2026) Table 143. Asia-Pacific Biologics for Severe Asthma Market Size Forecast by Country (2027-2032) & (US$ Million) Table 144. Asia-Pacific Biologics for Severe Asthma Market Share Forecast by Country (2027-2032) Table 145. Latin America Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 146. Latin America Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 147. Latin America Biologics for Severe Asthma Sales Market Share by Country (2021-2026) Table 148. Latin America Biologics for Severe Asthma Sales Forecast by Country (2027-2032) & (K Units) Table 149. Latin America Biologics for Severe Asthma Sales Market Share Forecast by Country (2027-2032) Table 150. Latin America Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 151. Latin America Biologics for Severe Asthma Market Size by Country (2021-2026) & (US$ Million) Table 152. Latin America Biologics for Severe Asthma Market Share by Country (2021-2026) Table 153. Latin America Biologics for Severe Asthma Market Size Forecast by Country (2027-2032) & (US$ Million) Table 154. Latin America Biologics for Severe Asthma Market Share Forecast by Country (2027-2032) Table 155. Middle East and Africa Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 156. Middle East and Africa Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 157. Middle East and Africa Biologics for Severe Asthma Sales Market Share by Country (2021-2026) Table 158. Middle East and Africa Biologics for Severe Asthma Sales Forecast by Country (2027-2032) & (K Units) Table 159. Middle East and Africa Biologics for Severe Asthma Sales Market Share Forecast by Country (2027-2032) Table 160. Middle East and Africa Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 161. Middle East and Africa Biologics for Severe Asthma Market Size by Country (2021-2026) & (US$ Million) Table 162. Middle East and Africa Biologics for Severe Asthma Market Share by Country (2021-2026) Table 163. Middle East and Africa Biologics for Severe Asthma Market Size Forecast by Country (2027-2032) & (US$ Million) Table 164. Middle East and Africa Biologics for Severe Asthma Market Share Forecast by Country (2027-2032) Table 165. Key Raw Materials Table 166. Raw Materials Key Suppliers Table 167. Biologics for Severe Asthma Distributors List Table 168. Biologics for Severe Asthma Customers List Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Biologics for Severe Asthma Image Figure 2. Global Biologics for Severe Asthma Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics for Severe Asthma Market Size (2021-2032) & (US$ Million) Figure 4. Global Biologics for Severe Asthma Sales (2021-2032) & (K Units) Figure 5. Omalizumab Image Figure 6. Global Omalizumab Sales YoY Growth (2021-2032) & (K Units) Figure 7. Benralizumab Image Figure 8. Global Benralizumab Sales YoY Growth (2021-2032) & (K Units) Figure 9. Dupirumab Image Figure 10. Global Dupirumab Sales YoY Growth (2021-2032) & (K Units) Figure 11. Mepolizumab Image Figure 12. Global Mepolizumab Sales YoY Growth (2021-2032) & (K Units) Figure 13. Reslizumab Image Figure 14. Global Reslizumab Sales YoY Growth (2021-2032) & (K Units) Figure 15. Tezepelumab-ekko Image Figure 16. Global Tezepelumab-ekko Sales YoY Growth (2021-2032) & (K Units) Figure 17. Global Biologics for Severe Asthma Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Biologics for Severe Asthma Market Share by Type 2025 VS 2032 Figure 19. North America Biologics for Severe Asthma Sales Market Share in Volume by Type in 2025 Figure 20. North America Biologics for Severe Asthma Sales Market Share in Value by Type in 2025 Figure 21. Europe Biologics for Severe Asthma Sales Market Share in Volume by Type in 2025 Figure 22. Europe Biologics for Severe Asthma Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Biologics for Severe Asthma Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Biologics for Severe Asthma Sales Market Share in Value by Type in 2025 Figure 25. Latin America Biologics for Severe Asthma Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Biologics for Severe Asthma Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Biologics for Severe Asthma Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Biologics for Severe Asthma Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Biologics for Severe Asthma Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 33. Hospital Image Figure 34. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 35. Other Image Figure 36. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 37. Global Biologics for Severe Asthma Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Biologics for Severe Asthma Market Share by Application 2025 VS 2032 Figure 39. North America Biologics for Severe Asthma Sales Market Share in Volume by Application in 2025 Figure 40. North America Biologics for Severe Asthma Sales Market Share in Value by Application in 2025 Figure 41. Europe Biologics for Severe Asthma Sales Market Share in Volume by Application in 2025 Figure 42. Europe Biologics for Severe Asthma Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Biologics for Severe Asthma Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Biologics for Severe Asthma Sales Market Share in Value by Application in 2025 Figure 45. Latin America Biologics for Severe Asthma Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Biologics for Severe Asthma Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Biologics for Severe Asthma Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Biologics for Severe Asthma Sales Market Share in Value by Application in 2025 Figure 49. North America Biologics for Severe Asthma Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. North America Biologics for Severe Asthma Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Biologics for Severe Asthma Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Biologics for Severe Asthma Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Biologics for Severe Asthma Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Europe Biologics for Severe Asthma Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Biologics for Severe Asthma Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Biologics for Severe Asthma Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Biologics for Severe Asthma Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Asia-Pacific Biologics for Severe Asthma Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Biologics for Severe Asthma Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Biologics for Severe Asthma Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Biologics for Severe Asthma Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Latin America Biologics for Severe Asthma Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Biologics for Severe Asthma Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Biologics for Severe Asthma Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Biologics for Severe Asthma Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Middle East and Africa Biologics for Severe Asthma Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Biologics for Severe Asthma Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Biologics for Severe Asthma Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Biologics for Severe Asthma Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Biologics for Severe Asthma Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Omalizumab
  • Benralizumab
  • Dupirumab
  • Mepolizumab
  • Reslizumab
  • Tezepelumab-ekko
Applications
  • Clinic
  • Hospital
  • Other
Companies covered
  • Teva Pharmaceuticals
  • Sanofi
  • Novartis
  • Roche
  • Regeneron Pharmaceuticals
  • GSK
  • AstraZeneca
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biologics for Severe Asthma Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Biologics for Severe Asthma Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Biologics for Severe Asthma Market by Type
  6. 1.3.1 Omalizumab
  7. 1.3.2 Benralizumab
  8. 1.3.3 Dupirumab
  9. 1.3.4 Mepolizumab
  10. 1.3.5 Reslizumab
  11. 1.3.6 Tezepelumab-ekko
  12. 1.4 Global Biologics for Severe Asthma Market Size by Type
  13. 1.4.1 Global Biologics for Severe Asthma Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Biologics for Severe Asthma Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Biologics for Severe Asthma Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Biologics for Severe Asthma Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Biologics for Severe Asthma Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Biologics for Severe Asthma Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Biologics for Severe Asthma Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Biologics for Severe Asthma Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Biologics for Severe Asthma Industry Trends
  2. 2.2 Biologics for Severe Asthma Industry Drivers
  3. 2.3 Biologics for Severe Asthma Industry Opportunities and Challenges
  4. 2.4 Biologics for Severe Asthma Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Biologics for Severe Asthma Revenue (2021-2026)
  2. 3.2 Global Top Players by Biologics for Severe Asthma Sales (2021-2026)
  3. 3.3 Global Top Players by Biologics for Severe Asthma Price (2021-2026)
  4. 3.4 Global Biologics for Severe Asthma Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biologics for Severe Asthma Major Company Production Sites & Headquarters
  6. 3.6 Global Biologics for Severe Asthma Company, Product Type & Application
  7. 3.7 Global Biologics for Severe Asthma Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biologics for Severe Asthma Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biologics for Severe Asthma Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biologics for Severe Asthma Tier 1, Tier 2, and Tier 3
4 Biologics for Severe Asthma Regional Status and Outlook
  1. 4.1 Global Biologics for Severe Asthma Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Biologics for Severe Asthma Historic Market Size by Region
  3. 4.2.1 Global Biologics for Severe Asthma Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Biologics for Severe Asthma Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Biologics for Severe Asthma Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Biologics for Severe Asthma Forecasted Market Size by Region
  7. 4.3.1 Global Biologics for Severe Asthma Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Biologics for Severe Asthma Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Biologics for Severe Asthma Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Biologics for Severe Asthma by Application
  1. 5.1 Biologics for Severe Asthma Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Other
  5. 5.2 Global Biologics for Severe Asthma Market Size by Application
  6. 5.2.1 Global Biologics for Severe Asthma Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Biologics for Severe Asthma Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Biologics for Severe Asthma Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Biologics for Severe Asthma Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Biologics for Severe Asthma Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Biologics for Severe Asthma Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Biologics for Severe Asthma Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Biologics for Severe Asthma Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Teva Pharmaceuticals
  2. 6.1.1 Teva Pharmaceuticals Company Information
  3. 6.1.2 Teva Pharmaceuticals Business Overview
  4. 6.1.3 Teva Pharmaceuticals Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolio
  6. 6.1.5 Teva Pharmaceuticals Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Biologics for Severe Asthma Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novartis Biologics for Severe Asthma Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Roche
  20. 6.4.1 Roche Company Information
  21. 6.4.2 Roche Business Overview
  22. 6.4.3 Roche Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Roche Biologics for Severe Asthma Product Portfolio
  24. 6.4.5 Roche Recent Developments
  25. 6.5 Regeneron Pharmaceuticals
  26. 6.5.1 Regeneron Pharmaceuticals Company Information
  27. 6.5.2 Regeneron Pharmaceuticals Business Overview
  28. 6.5.3 Regeneron Pharmaceuticals Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolio
  30. 6.5.5 Regeneron Pharmaceuticals Recent Developments
  31. 6.6 GSK
  32. 6.6.1 GSK Company Information
  33. 6.6.2 GSK Business Overview
  34. 6.6.3 GSK Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 GSK Biologics for Severe Asthma Product Portfolio
  36. 6.6.5 GSK Recent Developments
  37. 6.7 AstraZeneca
  38. 6.7.1 AstraZeneca Company Information
  39. 6.7.2 AstraZeneca Business Overview
  40. 6.7.3 AstraZeneca Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 AstraZeneca Biologics for Severe Asthma Product Portfolio
  42. 6.7.5 AstraZeneca Recent Developments
  43. 6.8 Amgen
  44. 6.8.1 Amgen Company Information
  45. 6.8.2 Amgen Business Overview
  46. 6.8.3 Amgen Biologics for Severe Asthma Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Amgen Biologics for Severe Asthma Product Portfolio
  48. 6.8.5 Amgen Recent Developments
7 North America by Country
  1. 7.1 North America Biologics for Severe Asthma Sales by Country
  2. 7.1.1 North America Biologics for Severe Asthma Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Biologics for Severe Asthma Sales by Country (2021-2026)
  4. 7.1.3 North America Biologics for Severe Asthma Sales Forecast by Country (2027-2032)
  5. 7.2 North America Biologics for Severe Asthma Market Size by Country
  6. 7.2.1 North America Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Biologics for Severe Asthma Market Size by Country (2021-2026)
  8. 7.2.3 North America Biologics for Severe Asthma Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Biologics for Severe Asthma Sales by Country
  2. 8.1.1 Europe Biologics for Severe Asthma Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Biologics for Severe Asthma Sales by Country (2021-2026)
  4. 8.1.3 Europe Biologics for Severe Asthma Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Biologics for Severe Asthma Market Size by Country
  6. 8.2.1 Europe Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Biologics for Severe Asthma Market Size by Country (2021-2026)
  8. 8.2.3 Europe Biologics for Severe Asthma Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Biologics for Severe Asthma Sales by Country
  2. 9.1.1 Asia-Pacific Biologics for Severe Asthma Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Biologics for Severe Asthma Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Biologics for Severe Asthma Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Biologics for Severe Asthma Market Size by Country
  6. 9.2.1 Asia-Pacific Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Biologics for Severe Asthma Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Biologics for Severe Asthma Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Biologics for Severe Asthma Sales by Country
  2. 10.1.1 South America Biologics for Severe Asthma Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Biologics for Severe Asthma Sales by Country (2021-2026)
  4. 10.1.3 South America Biologics for Severe Asthma Sales Forecast by Country (2027-2032)
  5. 10.2 South America Biologics for Severe Asthma Market Size by Country
  6. 10.2.1 South America Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Biologics for Severe Asthma Market Size by Country (2021-2026)
  8. 10.2.3 South America Biologics for Severe Asthma Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Biologics for Severe Asthma Sales by Country
  2. 11.1.1 Middle East and Africa Biologics for Severe Asthma Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Biologics for Severe Asthma Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Biologics for Severe Asthma Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Biologics for Severe Asthma Market Size by Country
  6. 11.2.1 Middle East and Africa Biologics for Severe Asthma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Biologics for Severe Asthma Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Biologics for Severe Asthma Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Biologics for Severe Asthma Value Chain Analysis
  2. 12.1.1 Biologics for Severe Asthma Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Biologics for Severe Asthma Production Mode & Process
  7. 12.2 Biologics for Severe Asthma Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Biologics for Severe Asthma Distributors
  10. 12.2.3 Biologics for Severe Asthma Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst